Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC). Fibroblast growth ...
Long-term safety was stable without emergent signals; grade ≥3 TRAEs stayed ~57–59%, while cumulative neuropathy increased with duration, managed via interruptions and EV dose reductions. Notably, ...
As of the April 20, 2026, data cut-off, 82 patients had been treated, and 72 had completed primary response evaluation. Dr.
Adjuvant pembrolizumab more than doubled disease-free survival (DFS) after radical surgery in patients with high-risk muscle-invasive urothelial cancer, according to new findings from the phase 3 ...
A urine tumor DNA test shows promise for noninvasive detection of bladder cancer and upper tract urothelial carcinoma, which may reduce the burden of cystoscopy. A multitarget urine tumor DNA test ...
Circulating tumor DNA (ctDNA) is an emerging technology that is rapidly transforming the management of patients with cancer -- not only in hematologic malignancies, but increasingly also in solid ...
The EMA has backed new and expanded uses for multiple cancer drugs, signaling a push toward biomarker-driven, earlier-line ...
Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and its efficacy was not inferior in patients with diabetes and/or neuropathy.
Preoperative CT radiomics–deep learning signature for lymphovascular invasion in bladder cancer: External validation and clinical utility. Prognostic significance of the preoperative De Ritis ratio ...
Early on-treatment weight loss was not associated with progression-free survival or time to discontinuation of enfortumab vedotin. Early weight loss after the start of first-line treatment with ...
They further applied two-sample Mendelian randomization (TSMR) analysis to examine genetic associations between prostate cancer and ten common secondary primary malignancies (SPMs). The study not only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results